CN117510623A - 一种CSFV E0蛋白的纳米抗体CSFV-E0-Nb1及编码基因和应用 - Google Patents
一种CSFV E0蛋白的纳米抗体CSFV-E0-Nb1及编码基因和应用 Download PDFInfo
- Publication number
- CN117510623A CN117510623A CN202311490452.8A CN202311490452A CN117510623A CN 117510623 A CN117510623 A CN 117510623A CN 202311490452 A CN202311490452 A CN 202311490452A CN 117510623 A CN117510623 A CN 117510623A
- Authority
- CN
- China
- Prior art keywords
- csfv
- protein
- detection
- quality control
- control line
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LXWYCLOUQZZDBD-LIYNQYRNSA-N csfv Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 LXWYCLOUQZZDBD-LIYNQYRNSA-N 0.000 title claims abstract description 113
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 71
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 63
- 238000001514 detection method Methods 0.000 claims abstract description 104
- 239000002096 quantum dot Substances 0.000 claims abstract description 47
- 238000012360 testing method Methods 0.000 claims abstract description 37
- 229940031626 subunit vaccine Drugs 0.000 claims abstract description 22
- 230000014509 gene expression Effects 0.000 claims abstract description 20
- 150000001413 amino acids Chemical group 0.000 claims abstract description 7
- 238000003908 quality control method Methods 0.000 claims description 55
- 101710125507 Integrase/recombinase Proteins 0.000 claims description 29
- 238000011534 incubation Methods 0.000 claims description 17
- 239000013604 expression vector Substances 0.000 claims description 16
- 238000010168 coupling process Methods 0.000 claims description 14
- 239000000047 product Substances 0.000 claims description 14
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 13
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 13
- 239000002773 nucleotide Substances 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 230000008878 coupling Effects 0.000 claims description 12
- 238000005859 coupling reaction Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 9
- 238000003259 recombinant expression Methods 0.000 claims description 8
- 238000007789 sealing Methods 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 5
- 230000003213 activating effect Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 230000001131 transforming effect Effects 0.000 claims description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 3
- 230000009465 prokaryotic expression Effects 0.000 claims description 3
- 238000003317 immunochromatography Methods 0.000 abstract description 23
- 241000282898 Sus scrofa Species 0.000 abstract description 9
- 238000000746 purification Methods 0.000 abstract description 9
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 206010037660 Pyrexia Diseases 0.000 abstract description 5
- 238000003748 differential diagnosis Methods 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 4
- 210000002966 serum Anatomy 0.000 description 23
- 239000000243 solution Substances 0.000 description 17
- 238000002965 ELISA Methods 0.000 description 16
- 238000002823 phage display Methods 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 208000015181 infectious disease Diseases 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 230000003053 immunization Effects 0.000 description 11
- 230000027455 binding Effects 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 9
- 238000002649 immunization Methods 0.000 description 9
- 210000004698 lymphocyte Anatomy 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 238000004091 panning Methods 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 238000012795 verification Methods 0.000 description 7
- 241001416177 Vicugna pacos Species 0.000 description 6
- 239000000287 crude extract Substances 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 239000007790 solid phase Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- 241000710777 Classical swine fever virus Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 239000008118 PEG 6000 Substances 0.000 description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 2
- 241000702619 Porcine parvovirus Species 0.000 description 2
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 2
- 108091011223 Transmembrane protein 121 Proteins 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 229940031567 attenuated vaccine Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- UHYPYGJEEGLRJD-UHFFFAOYSA-N cadmium(2+);selenium(2-) Chemical compound [Se-2].[Cd+2] UHYPYGJEEGLRJD-UHFFFAOYSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000012917 library technology Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 208000001726 Classical Swine Fever Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 239000012880 LB liquid culture medium Substances 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 101100002024 Thermus aquaticus pstI gene Proteins 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000670 ligand binding assay Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54346—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
- G01N33/587—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/588—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with semiconductor nanocrystal label, e.g. quantum dots
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/101—Plasmid DNA for bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
- G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Materials Engineering (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311490452.8A CN117510623A (zh) | 2023-11-09 | 2023-11-09 | 一种CSFV E0蛋白的纳米抗体CSFV-E0-Nb1及编码基因和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311490452.8A CN117510623A (zh) | 2023-11-09 | 2023-11-09 | 一种CSFV E0蛋白的纳米抗体CSFV-E0-Nb1及编码基因和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117510623A true CN117510623A (zh) | 2024-02-06 |
Family
ID=89752480
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311490452.8A Pending CN117510623A (zh) | 2023-11-09 | 2023-11-09 | 一种CSFV E0蛋白的纳米抗体CSFV-E0-Nb1及编码基因和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117510623A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101900731A (zh) * | 2010-08-05 | 2010-12-01 | 中国兽医药品监察所 | 一种区别检测猪瘟疫苗免疫与野毒感染抗体的elisa试剂盒及其制备方法 |
EP3084441A1 (en) * | 2013-12-19 | 2016-10-26 | Intervet International B.V. | Improved diagnostic test for csfv antibodies |
CN109187969A (zh) * | 2018-09-19 | 2019-01-11 | 天康生物股份有限公司 | 检测猪瘟病毒抗体的免疫层析试纸、试剂盒和用途 |
CN109738639A (zh) * | 2019-01-31 | 2019-05-10 | 湖南农业大学 | 一种检测猪瘟病毒e0蛋白抗体的elisa试剂盒 |
CN114957454A (zh) * | 2022-05-25 | 2022-08-30 | 青岛农业大学 | 一种抗csfv e2蛋白的纳米抗体、融合蛋白及其制备方法和应用 |
-
2023
- 2023-11-09 CN CN202311490452.8A patent/CN117510623A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101900731A (zh) * | 2010-08-05 | 2010-12-01 | 中国兽医药品监察所 | 一种区别检测猪瘟疫苗免疫与野毒感染抗体的elisa试剂盒及其制备方法 |
EP3084441A1 (en) * | 2013-12-19 | 2016-10-26 | Intervet International B.V. | Improved diagnostic test for csfv antibodies |
CN109187969A (zh) * | 2018-09-19 | 2019-01-11 | 天康生物股份有限公司 | 检测猪瘟病毒抗体的免疫层析试纸、试剂盒和用途 |
CN109738639A (zh) * | 2019-01-31 | 2019-05-10 | 湖南农业大学 | 一种检测猪瘟病毒e0蛋白抗体的elisa试剂盒 |
CN114957454A (zh) * | 2022-05-25 | 2022-08-30 | 青岛农业大学 | 一种抗csfv e2蛋白的纳米抗体、融合蛋白及其制备方法和应用 |
Non-Patent Citations (3)
Title |
---|
YU-LIANG HUANG: "The challenges of classical swine fever control: Modified live and E2 subunit vaccines", 《VIRUS RESEARCH》, vol. 179, 6 November 2013 (2013-11-06), pages 1 - 11, XP028820157, DOI: 10.1016/j.virusres.2013.10.025 * |
郭东光: "猪瘟病毒结构蛋白E0 抗体间接ELISA 检测方法的建立及优化", 《河南农业科学》, vol. 48, no. 11, 31 December 2019 (2019-12-31), pages 151 - 156 * |
马 帅: "我国猪瘟的流行病学及疫苗研究进展", 《中国动物传染病学报》, vol. 30, no. 6, 31 December 2022 (2022-12-31), pages 211 - 218 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110776564B (zh) | 两株抗新城疫病毒纳米抗体及其表达制备方法和应用 | |
CN114957454B (zh) | 一种抗csfv e2蛋白的纳米抗体、融合蛋白及其制备方法和应用 | |
CN114088944B (zh) | 基于纳米抗体的犬瘟热病毒抗原检测试纸条及其制备方法 | |
US20230193194A1 (en) | Generic inert bio-vector salmonella sp. and potential uses thereof | |
CN113684189A (zh) | 一株鸡新型圆圈病毒3型毒株及基于该病毒的检测体系 | |
CN105061602B (zh) | 用于检测抗猪产肠毒素性大肠杆菌抗体的融合蛋白、制备方法及应用 | |
CN110016078B (zh) | 一种基于pedv n蛋白特异性纳米抗体的阻断elisa的检测方法及其应用 | |
CN115073613A (zh) | 一种融合蛋白GLuc-p30及其制备方法和应用 | |
CN113588946B (zh) | 一种猪肺炎支原体抗体间接elisa检测用的重组蛋白和方法 | |
CN114316035A (zh) | 一种通用型的口蹄疫病毒结构蛋白抗体、制备方法及其应用 | |
CN109239341B (zh) | 一种牛溶血性曼氏杆菌抗体检测的间接elisa试剂盒及其应用 | |
US20230375548A1 (en) | Indirect enzyme-linked immunosorbent assay detection kit based on p30 protein and p22 protein of african swine fever virus | |
CN113388039A (zh) | Sars-cov-2冠状病毒的抗原模拟表位和免疫层析试纸条 | |
CN111073859A (zh) | 一种检测牛细小病毒的双抗体夹心elisa试剂盒及其应用 | |
CN117510623A (zh) | 一种CSFV E0蛋白的纳米抗体CSFV-E0-Nb1及编码基因和应用 | |
CN116449002A (zh) | 一种筛查疫苗免疫和新型冠状病毒感染的胶体金层析试纸条及其应用 | |
CN113583118B (zh) | 用于检测番鸭呼肠孤病毒的单链抗体、嵌合抗体和双夹心elisa检测试剂盒 | |
CN111208302B (zh) | 利用多表位串联蛋白检测猪口蹄疫o型抗体的化学发光检测试剂盒 | |
CN111929438B (zh) | 一种检测非洲猪瘟病毒抗体的量子点微球免疫层析试纸条及其应用 | |
CN113884674A (zh) | 一种牛支原体胶体金免疫检测试纸条、制备方法及其应用 | |
CN113583141A (zh) | 猪流行性腹泻病毒Nsp9蛋白、含该Nsp9蛋白的融合蛋白及其制备方法和应用 | |
CN113735968A (zh) | 一种猪传染性胃肠炎病毒n蛋白抗体效价测定方法 | |
CN105334322B (zh) | 一种水泡性口炎病毒重组n蛋白抗原及其制备方法 | |
CN116715737B (zh) | 新型冠状病毒受体结合域B细胞表位的靶标抗原及其在Peg菌毛展呈表达及应用 | |
CN114685619B (zh) | 一种抗原蛋白、其单克隆抗体或多克隆抗体及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Cao Zhi Inventor after: Li Wenling Inventor after: Zhang Lihong Inventor after: Yin Dehua Inventor after: Li Siyu Inventor after: Zhang Yixin Inventor after: Wang Xiaoduo Inventor after: Li Shuo Inventor before: Li Wenling Inventor before: Zhang Lihong Inventor before: Cao Zhi Inventor before: Yin Dehua Inventor before: Li Siyu Inventor before: Zhang Yixin Inventor before: Wang Xiaoduo Inventor before: Li Shuo |